Home > Insider Trading > Filing (0001209191-22-060970)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1818794	Dyne Therapeutics Inc.	DYN	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1691005	Gatti Susanna High	C/O Dyne Therapeutics, Inc. 1560 Trapelo Road Waltham MA 02451	Chief Operating Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2022-12-09	44,000	$0.00	112,786	No	4	A	Direct
Common Stock	Disposition	2022-12-12	751	$10.87	112,035	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	A	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Acquisiton	2022-12-09	69,000	$0.00	69,000	$10.72

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
69,000		2032-12-08	No	4	A	Direct

Footnotes

Consists of shares of Common Stock issuable under 44,000 restricted stock units ("RSUs"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal quarterly installments over four years with the first installment vesting on March 10, 2023.
Includes 94,710 unvested RSUs.
Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.
Includes 92,191 unvested RSUs.
This option was granted on December 9, 2022. The shares underlying the option are scheduled to vest over four years in equal monthly installments through December 10, 2026.